247 related articles for article (PubMed ID: 36861174)
21. Chemotherapy or chemo-immunotherapy as first-line treatment for extensive-stage small-cell lung cancer: a meta-analysis.
Chen CY; Chen WC; Hung CM; Wei YF
Immunotherapy; 2021 Oct; 13(14):1165-1177. PubMed ID: 34261336
[TBL] [Abstract][Full Text] [Related]
22. Cytokines Orchestrating the Natural Killer-Myeloid Cell Crosstalk in the Tumor Microenvironment: Implications for Natural Killer Cell-Based Cancer Immunotherapy.
Gaggero S; Witt K; Carlsten M; Mitra S
Front Immunol; 2020; 11():621225. PubMed ID: 33584718
[TBL] [Abstract][Full Text] [Related]
23. Natural killer cells as a double-edged sword in cancer immunotherapy: A comprehensive review from cytokine therapy to adoptive cell immunotherapy.
Wu Y; Li J; Jabbarzadeh Kaboli P; Shen J; Wu X; Zhao Y; Ji H; Du F; Zhou Y; Wang Y; Zhang H; Yin J; Wen Q; Cho CH; Li M; Xiao Z
Pharmacol Res; 2020 May; 155():104691. PubMed ID: 32070721
[TBL] [Abstract][Full Text] [Related]
24. Survival and pretreatment prognostic factors for extensive-stage small cell lung cancer: A comprehensive analysis of 358 patients.
Huang LL; Hu XS; Wang Y; Li JL; Wang HY; Liu P; Xu JP; He XH; Hao XZ; Jiang PD; Liu YT; Luo J; Zhou SY; Wang JW; Yang JL; Qin Y; Yuan P; Lin L; Shi YK
Thorac Cancer; 2021 Jul; 12(13):1943-1951. PubMed ID: 33969619
[TBL] [Abstract][Full Text] [Related]
25. Prospects of targeted and immune therapies in SCLC.
Hendriks LEL; Menis J; Reck M
Expert Rev Anticancer Ther; 2019 Feb; 19(2):151-167. PubMed ID: 30590971
[No Abstract] [Full Text] [Related]
26. Prognostic factors affecting the risk of thoracic progression in extensive-stage small cell lung cancer.
Fukui T; Itabashi M; Ishihara M; Hiyoshi Y; Kasajima M; Igawa S; Sasaki J; Masuda N
BMC Cancer; 2016 Mar; 16():197. PubMed ID: 26955807
[TBL] [Abstract][Full Text] [Related]
27. Targeting Natural Killer Cells for Tumor Immunotherapy.
Zhang C; Hu Y; Shi C
Front Immunol; 2020; 11():60. PubMed ID: 32140153
[TBL] [Abstract][Full Text] [Related]
28. FOXP3-based immune risk model for recurrence prediction in small-cell lung cancer at stages I-III.
Jiang M; Wu C; Zhang L; Sun C; Wang H; Xu Y; Sun H; Zhu J; Zhao W; Fang Q; Yu J; Chen P; Wu S; Zheng Z; He Y; Zhou C
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34006632
[TBL] [Abstract][Full Text] [Related]
29. Use of Immunotherapy in Extensive-Stage Small Cell Lung Cancer.
Konala VM; Madhira BR; Ashraf S; Graziano S
Oncology; 2020; 98(11):749-754. PubMed ID: 32663833
[TBL] [Abstract][Full Text] [Related]
30. Anlotinib plus etoposide and cisplatin/carboplatin as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): a single-arm, phase II study.
Kong T; Chen L; Zhao X; Duan F; Zhou H; Wang L; Liu D
Invest New Drugs; 2022 Oct; 40(5):1095-1105. PubMed ID: 35788937
[TBL] [Abstract][Full Text] [Related]
31. Current and future therapeutic approaches for the treatment of small cell lung cancer.
Rossi A; Tay R; Chiramel J; Prelaj A; Califano R
Expert Rev Anticancer Ther; 2018 May; 18(5):473-486. PubMed ID: 29544351
[TBL] [Abstract][Full Text] [Related]
32. Galectin-9-based immune risk score model helps to predict relapse in stage I-III small cell lung cancer.
Chen P; Zhang L; Zhang W; Sun C; Wu C; He Y; Zhou C
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33082168
[TBL] [Abstract][Full Text] [Related]
33. Challenges in the treatment of small cell lung cancer in the era of immunotherapy and molecular classification.
Caliman E; Fancelli S; Petroni G; Gatta Michelet MR; Cosso F; Ottanelli C; Mazzoni F; Voltolini L; Pillozzi S; Antonuzzo L
Lung Cancer; 2023 Jan; 175():88-100. PubMed ID: 36493578
[TBL] [Abstract][Full Text] [Related]
34. Evasion of Innate Immunity Contributes to Small Cell Lung Cancer Progression and Metastasis.
Zhu M; Huang Y; Bender ME; Girard L; Kollipara R; Eglenen-Polat B; Naito Y; Savage TK; Huffman KE; Koyama S; Kumanogoh A; Minna JD; Johnson JE; Akbay EA
Cancer Res; 2021 Apr; 81(7):1813-1826. PubMed ID: 33495232
[TBL] [Abstract][Full Text] [Related]
35. Natural Killer Cells as a Potential Biomarker for Predicting Immunotherapy Efficacy in Patients with Non-Small Cell Lung Cancer.
Cho YH; Choi MG; Kim DH; Choi YJ; Kim SY; Sung KJ; Lee JC; Kim SY; Rho JK; Choi CM
Target Oncol; 2020 Apr; 15(2):241-247. PubMed ID: 32285316
[TBL] [Abstract][Full Text] [Related]
36. Ferroptosis, necroptosis, and pyroptosis in the tumor microenvironment: Perspectives for immunotherapy of SCLC.
Niu X; Chen L; Li Y; Hu Z; He F
Semin Cancer Biol; 2022 Nov; 86(Pt 3):273-285. PubMed ID: 35288298
[TBL] [Abstract][Full Text] [Related]
37. [Immunotherapy Advances in Small Cell Lung Cancer].
Xu Y; Zhan P; Song Y
Zhongguo Fei Ai Za Zhi; 2020 Nov; 23(11):989-998. PubMed ID: 32752583
[TBL] [Abstract][Full Text] [Related]
38. Emerging Strategies for the Treatment of Small Cell Lung Cancer: A Review.
Petty WJ; Paz-Ares L
JAMA Oncol; 2023 Mar; 9(3):419-429. PubMed ID: 36520421
[TBL] [Abstract][Full Text] [Related]
39. Role of natural killer cells in lung cancer.
Aktaş ON; Öztürk AB; Erman B; Erus S; Tanju S; Dilege Ş
J Cancer Res Clin Oncol; 2018 Jun; 144(6):997-1003. PubMed ID: 29616326
[TBL] [Abstract][Full Text] [Related]
40. Neuron-specific enolase and response to initial therapy are important prognostic factors in patients with small cell lung cancer.
Zhou M; Wang Z; Yao Y; Zhou H; Liu M; Sun J
Clin Transl Oncol; 2017 Jul; 19(7):865-873. PubMed ID: 28127669
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
